August 19, 2013 -- Novartis, a Basel, Switzerland-based healthcare solutions company, announced on Thursday that the Australian Therapeutic Goods Administration added the company’s meningococcal B vaccine to the Australian Register of Therapeutic Goods.
Bexsero, Novartis’ multi-component MenB vaccine suspension for injection, was approved for use in individuals two months of age and older. The vaccine is the first and only broad coverage vaccine to help protect all age groups against MenB, including infants.
“Novartis welcomes the Australian health authorities’ decision to license Bexsero, which is further testament to the vaccine’s demonstrated robust efficacy and safety profiles and an important step in preventing further suffering caused by MenB disease,” Andrin Oswald, the division head of Novartis Vaccines and Diagnostics, said. “We are committed to bringing Bexsero to parents around the globe that want to protect their children against this devastating disease.”
Read the rest of the article here.